Back in April, I wrote about one of our newer portfolio companies, HexemBio, and their idea that reframed aging for me: people don’t die of old age, they die of aging blood. As blood stem cells decline, immunity weakens and disease follows.
We invested because they rejuvenate a patient’s own cells instead of reprogramming them.
Now they’re unveiling a three-generation product line off of their core technology. The transplant therapy program, an injectable, and a skin and wound product.
That’s all that you can hope for when you back foundational science. You invest in one massive idea that turns into several products that can change the face of healthcare, because the underlying insight is so strong.
Congratulations to Gabriel Levesque Tremblay and team. We’re looking forward to what’s coming next!
We invested because they rejuvenate a patient’s own cells instead of reprogramming them.
Now they’re unveiling a three-generation product line off of their core technology. The transplant therapy program, an injectable, and a skin and wound product.
That’s all that you can hope for when you back foundational science. You invest in one massive idea that turns into several products that can change the face of healthcare, because the underlying insight is so strong.
Congratulations to Gabriel Levesque Tremblay and team. We’re looking forward to what’s coming next!
